




FFW

Docket No. 5197-103 US

The undersigned certifies that this communication is being deposited with the United States Postal Service as prepaid first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on April 21, 2006.


Diane Dunn McKay

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	:	Customer No.
DUCHARME et al.	:	26817
	:	
Serial No. 10/826,240	:	Group Art Unit: 3762
	:	
Filed: April 15, 2004	:	Examiner: TBD
	:	
Title: METHOD AND COMPOUNDS TO	:	Confirmation No. 9362
DECREASE THE INCIDENCE OF ATRIAL	:	
FIBRILLATION (AF) IN PATIENTS WITH	:	
LEFT VENTRICULAR DYSFUNCTION	:	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, Applicant hereby brings to the attention of the United States Patent and Trademark Office the following documents of which Applicant has been made aware. The documents are listed on the attached PTO Form 1449.


Pursuant to the OG Notice of August 5, 2003 for U.S. national applications filed after June 30, 2003, the requirement for submitting a copy of each cited U.S. patent and each cited U.S. patent application publication as this requirement is waived, copies of the U.S. patents and U.S. patent application publications are not submitted

Applicant submits that this Supplemental Information Disclosure Statement is submitted prior to a first action on the merits.

It is requested that the references be considered by the Examiner and be made of record as part of the available prior art under 37 C.F.R. § 1.104.

Respectfully submitted,

Dated: April 21, 2006



Diane Dunn McKay
Reg. No. 34,586
Attorney for Applicant

MATHEWS, SHEPHERD, McKAY & BRUNEAU, P.A.
100 Thanet Circle, Suite 306
Princeton, NJ 08540
Tel: 609 924 8555
Fax: 609 924 3036

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) 5197-103 US	Application Number 10/826,240
		Applicant(s) DUCHARME et al.	
		Filing Date 04/15/2004	Group Art Unit 3762
*EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		
	http://www.aboutatrialfibrillation.com/whatisaf.html		
1			
2	CARSON, Peter E. et al., "The Influence of Atrial Fibrillation on Prognosis in Mild to Moderate Heart Failure - The V-HeFT Studies", Circulation, Supplement VI, 87:6, pp VII02-VII10, (June 1993);		
3	MIDDLEKAUFF, Holly R. et al., "Prognostic Significance of Atrial Fibrillation in Advanced Heart Failure - A Study of 390 Patients", Circulation, 84:1, pp 40-48, (July 1991);		
4	POZZOLI, Massimo et al., "Predictors of Primary Atrial Fibrillation and Concomitant Clinical and Hemodynamic Changes in Patients With Chronic Heart Failure: A Prospective Study in 344 Patients With Baseline Sinus Rhythm", JACC, 32:1, pp 197-204, (July 1998);		
5	DRIES, Daniel L. et al., "Atrial Fibrillation Is Associated With an Increased Risk for Mortality and Heart Failure Progression in Patients With Asymptomatic and Symptomatic Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SOLVD Trials", JACC, 32:3, pp 695-703, (September 1998);		
6	BOURASSA, Martial G. et al., "Natural History and Patterns of Current Practice in Heart Failure", JACC, Supplement A, 22:4, pp 14A-19A, (October 1993);		
7	MATHEW, James et al., "Incidence, Predictive Factors, and Prognostic Significance of Supraventricular Tachyarrhythmias, in Congestive Heart Failure", CHEST, 118:4, 914-922, (October 2000);		
8	LI, Danshi et al., "Promotion of Atrial Fibrillation by Heart Failure in Dogs - Atrial Remodeling of a Different Sort", Circulation, 100, pp 87-95, (July 6, 1999);		
9	SHI, Yanfen et al., "Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation", Cardiovascular Research, 52, pp 219-225, (2001);		
10	LI, Danshi et al., "Effects of Angiotensin-Converting Enzyme Inhibition on the Development of the Atrial Fibrillation Substrate in Dogs With Ventricular Tachypacing-Induced Congestive Heart Failure", Circulation, 104, pp 2608-2614, (November 20, 2001);		
11	SHI, Yanfen et al., "Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure", Cardiovascular Research, 54, pp 456-461, (2002);		
12	THE SOLVD INVESTIGATORS, "Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure", The New England Journal of Medicine, 325:5, pp 293-302, (August 1, 1991);		
EXAMINER		DATE CONSIDERED	

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) 5197-103 US		Application Number 10/862,240	
		Applicant(s) DUCHARME et al.			
		Filing Date 04/15/2004		Group Art Unit 3762	
*EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>				
13	THE SOLVD INVESTIGATORS, "Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions", The New England Journal of Medicine, 327:10, pp 685-691, (September 3, 1992);				
14	THE SOLVD INVESTIGATORS, "Studies of Left Ventricular Dysfunction (SOLVD) - Rationale, Design and Methods: Two Trials That Evaluate the Effect of Enalapril on Patients with Reduced Ejection Fraction", The American Journal of Cardiology, 66, pp 315-322, (August 1, 1990);				
15	FUSTER, Valentin et al., "ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary", JACC, 38:4, pp 1231-1265, (October 2001);				
16	ST. JOHN SUTTON, Martin et al., "Quantitative Two-dimensional Echocardiographic Measurements Are Major Predictors of Adverse Cardiovascular Events After Acute Myocardial Infarction - The Protective Effects of Captopril", Circulation, 89:1, pp 68-75, (January 1994);				
17	ZOU, Yunzeng et al., "Cell Type-Specific Angiotensin II-Evoked Signal Transduction Pathways - Critical Roles of G Subunit, Src Family, and Ras in Cardiac Fibroblasts", Circ. Res., 82, pp 337-345, (1998);				
18	PAGES, Gilles et al., "Mitogen-activated protein kinases p42 and p44 are required for fibroblast proliferation", Proc. Nat. Acad. Sci., 90, pp 8319-8323, (September 1993);				
19	BRILLA, Christian G. et al., "Collagen Metabolism in Cultured Adult Rat Cardiac Fibroblasts: Response to Angiotensin II and Aldosterone", J. Mol. Cell Cardiol., 26, pp 809-820, (1994);				
20	GOETTE, Andreas et al., "Increased Expression of Extracellular Signal-Regulated Kinase and Angiotensin-Converting Enzyme in Human Atria During Atrial Fibrillation", JACC, 35:6, pp 1669-1677, (May 2000);				
21	GOTTE, Andreas et al., "Regulation of Angiotensin II Receptor Subtypes During Atrial Fibrillation in Humans", Circulation, 101, pp 2678-2681, (June 13, 2000);				
22	NAKASHIMA, Hideko et al., "Angiotensin II Antagonist Prevents Electrical Remodeling in Atrial Fibrillation", Circulation, 101, pp 2612-2617, (June 6, 2000);				
23	KAPRIELIAN, Raffi R. et al., "Angiotensin II Receptor Type 1 mRNA is Upregulated in Atria of Patients with End-stage Heart Failure", J. Mol. Cell. Cardiol., 29, pp 2299-2304, (1997);				
24	SOLTI, F. et al., "The effect of atrial dilatation on the genesis of atrial arrhythmias", Cardiovascular Research, 23, pp 882-886, (1989);				
EXAMINER			DATE CONSIDERED		
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) 5197-103 US		Application Number 10/826,240	
		Applicant(s) DUCHARME et al.			
		Filing Date 04/15/2004		Group Art Unit 3762	
*EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>				
25	RAVELLI, Flavia et al., "Effects of Atrial Dilatation on Refractory Period and Vulnerability to Atrial Fibrillation in the Isolated Langendorff-Perfused Rabbit Heart", Circulation, 96:5, pp 1686-1695, (September 2, 1997);				
26	WEBSTER, Mark W.I. et al., "Effect of Enalapril on Ventricular Arrhythmias in Congestive Heart Failure", The American Journal of Cardiology, 56, pp 566-569, (September 15, 1985);				
27	MADRID, Antonio H. et al., "Use of Irbesartan to Maintain Sinus Rhythm in Patients With Long-Lasting Persistent Atrial Fibrillation - A Prospective and Randomized Study", Circulation, 106, 331-336, (July 16, 2002);				
28	LAMASSA, Maria et al., "Characteristics, Outcome, and Care of Stroke Associated With Atrial Fibrillation in Europe: Data From a Multicenter Multinational Hospital-Based Registry (The European Community Stroke Project)", Stroke, 32, pp 392-398, (February 2001);				
29	BOSCH, Jackie et al., "Use of ramipril in preventing stroke: double blind randomised trial", BMJ, 324, pp 1-5, (March 23, 2002);				
30	SHINAGAWA, Kaori et al., "Dynamic Nature of Atrial Fibrillation Substrate During Development and Reversal of Heart Failure in Dogs", Circulation, 105, pp 2672-2678, (June 4, 2002);				
31	UENG, Kwo-Chang et al., "Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation - Results of a prospective and controlled study", European Heart Journal, 24, pp 2090-2098, (2003);				
32	THE AF-CHF TRIAL INVESTIGATORS, "Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: The Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial", American Heart Journal, 144:4 pp 597-607, (October 2002);				
33	THE HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS, "Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients", The New England Journal of Medicine, 342:3, pp 145-153, (January 20, 2000).				
EXAMINER			DATE CONSIDERED		
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>					